Topical cidofovir for the treatment of dermatologic conditions: Verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox

Dermatologic Clinics

Volumn 21, Issue 2, 2003, Pages 301-309

  Toro, Jorge R ^a   Sanchez, Samuel ^a,b   Turiansky, George ^c   Blauvelt, Andrew ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR;

BOWENOID PAPULOSIS; CARCINOMA IN SITU; CONDYLOMA; CONDYLOMA ACUMINATUM; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HERPES SIMPLEX; HUMAN; KAPOSI SARCOMA; MOLLUSCUM CONTAGIOSUM; PRIORITY JOURNAL; REVIEW; SMALLPOX; SQUAMOUS CELL CARCINOMA; VERRUCA VULGARIS; VULVA CANCER;

EID: 0038409057     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(02)00116-X     Document Type: Review

References (59)

1. Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997;126:257-63.
2. Lalezari J, Schacker T, Feinberg J, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997;176:892-8.
3. Snoeck R, Ranst MV, Andrei G, et al. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. N Engl J Med 1995;333:943-4.
4. Zabawski EJ, Sands B, Goetz D, et al. Treatment of verruca vulgaris with topical cidofovir. JAMA 1997;278:z1236.
5. Meadows KP, Tyring SK, Pavia AT, et al. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol 1997;133:987-90.
6. Toro JR, Wood L, Turner M. Topical cidofovir: a novel treatment for recalcitrant molluseum contagiosum in HIV infected children. Arch Dermatol 2000;136:983-5.
7. Xiong X, Smith JL, Chen MS. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother 1997;41:594-5.
8. Snoeck R, Sakuma T, De Clercq E, et al. (S)-1-(3-hydroxy-2-phosphonylmethoxypropy 1)cyto-sine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 1988;32:1839-44.
9. Ho HT, Woods KL, Bronson JJ, et al. Intracellular metabolism of the antiherpes agent (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine. Mol Pharmacol 1992;41:197-202.
10. Mendel DB, Barkhimer DB, Chen MS. Biochemical basis for increased susceptibility to cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity. Antimicrob Agents Chemother 1995;39:2120-2.
11. Cundy KC, Li ZH, Hitchcock MJ, et al. Pharmacokinetics of cidofovir in monkeys: evidence for a prolonged elimination phase representing phosphorylated drug. Drug Metab Dispos 1996;24:738-44.
12. Cundy KC, Lynch G, Lee WA. Bioavailability and metabolism of cidofovir following topical administration to rabbits. Antiviral Res 1997;35:113-22.
13. Cundy KC, Petty BG, Flaherty J, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1995;39:1247-52.
14. Snoeck R, Wellens W, Deslooovere C, et al. Treatment of severe recurrent laryngeal papillomatosis by local injections of (S)-I-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine (cidofovir). Abstract presented at the 9th International Conference on Antiviral Research, Urbandai, Fuku-shima, Japan, May 19-24, 1996.
15. Bienvenu B, Martinez F, Devergie A, et al. Topical use of cidofovir induced acute renal failure. Transplantation 2002;73:661-2.
16. Andrei G, Snoeck R, Schols D, De Clercq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncology Research 2001;12:397-408.
17. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998;4:415-28.
18. Palefsky JM, Holley EA, Gonzales J, et al. Natural history of anal cytologic abnormalities and papilloma-virus infection among homosexual men with group IV HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1992;5:1258-65.
19. Critchlow CW, Surawicz Holmes KK, et al. Prospective study of high grade and squamous intraepidermal neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection. AIDS 1995;9:1255-62.
20. Unger ER, Vernon SD, Lee DR, et al. Human papillomavirus type in anal epithelial lesions is influenced by human immunodeficiency virus. Arch Pathol Lab Med 1997;121:820-4.
21. Palefsky JM, Holly EA, Ralston ML, et al. Prevalence and risk factors for human papillomavirus infection of the anal canal on HIV-positive and HIV-negative homosexual men. J Infect Dis 1998;177:361-7.
22. Palefsky JM, Shiboski S, Moss A. Risk factors for anal human papillomavirus infection and anal cytology abnormalities in HIV-positive and HIV-negative homosexual men. J Acquir Immnu Defic Syndr Hum Retrovirol. 1994;7:599-606.
23. Palefsky JM, Holley EA, Ralston ML, et al. High incidence of anal high-grade squamous intraepithelial lesions among HIV-positive and HIV-negative homosexual/bisexual men. AIDS 1998;12:495-503.
24. Della Torre G, Donghi R, Longoni A, et al. HPV DNA in intraepithelial neoplasia and carcinoma of the vulva and penis. Diagn Mol Pathol 1992;1:25-30.
25. Ikenberg H, Spitz C, Schmitt B, et al. Human papillomavirus DNA on locally recurrent cervical cancer. Gynecol Oncol 1994;52:332-6.
26. Goldie SJ, Kuntz KM, Weinstein MC, et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999;19:1822-9.
27. Hammer SM, Squires KE, Hughes MD, et al. for the AIDS Clinical Trials Group 320 Study Team. A control trial of two nucleoside analogues plus indinavir in persons with human immununodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
28. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamuvidine for HIV-1 infection, 100 week follow-up. JAMA 1998;280:35-41.
29. Koonsaeng S, Verschraegen C, Freedman R, et al. Successful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with cidofovir. J Med Virol 2001;6:195-8.
30. Snoeck R, Noel JC, Muller C, De Clercq E, Bossens M. Cidofovir, a new approach for the treatment of cervical intraepithelial neoplasia grade III (CIN III). J Med Virol 2000;60:205-9.
31. Snoeck R, Van Laethem Y, De Clercq E, et al. Treatment of a bowenoid papulosis of the penis with local applications of cidofovir in a patient with acquired immunodeficiency syndrome. Arch Intern Med 2001;161:2382-4.
32. Snoeck R, Bossens M, Parent D, et al. Phase II doubleblind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis 2001;33:597-602.
33. Matteelli A, Beltrame A, Graifemberghi S, et al. Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons. Sex Transm Dis 2001;28:343-6.
34. Davis MD, Gostout BS, McGovern RM, et al. Large plantar wart caused by human papillomavirus-66 and resolution by topical cidofovir therapy. J Am Acad Dermatol 2000;43:340-3.
35. Calista D. Resolution of recalcitrant human papillomavirus gingival infection with topical cidofovir. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:713-5.
36. Calista D. Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study. J Eur Acad Dermatol Venereol 2000;14:484-8.
37. Davies EG, Thrasher A, Lacey K, et al. Topical cidofovir for severe molluscum contagiosum. Lancet 1999;12;353:2042.
38. Bartlett JG. Protease inhibitors for HIV infection. Ann Intern Med 1996;124:1086-8.
39. Campbell TB, Borok M, Gwanzura L, et al. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 2000;14:2109-16.
40. Naesens L, Snoeck R, Andrei G, et al. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antivir Chem Chemother 1997;8:1-23.
41. Simonart T, Noel JC, De Dobbeleer G, et al. Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir: report of a case. J Med Virol 1998;55:215-8.
42. Kedes DH, Gane D. Sensitivity of Kaposi's sarcoma associated herpes virus replication to antiviral drugs: implications for potential therapy. J Clin Invest 1997;99:2082-6.
43. Medveczky MM, Orvath E, Lund T, et al. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpes virus. AIDS 1997;11:1327-32.
44. Mazzi R, Parisi SG, Sarmati L, et al. Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS. AIDS 2001;15:2061-2.
45. Saint-Leger E, Fillet AM, Malvy D, et al. Efficacy of cidofovir in an HIV infected patient with acyclovir and foscarnet resistant herpes simplex virus infection. Ann Dermatol Venereol 2001;128:747-9.
46. Lateef F, Donn PC, Kaufmann M, et al. Treatment of acyclovir-resistant foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS. Arch Dermatol 1998;134:1169-70.
47. Snoeck R, Andrei G, Gerard M, et al. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis 1994;8:570-8.
48. Lalezari J, Schacker T, Feinberg J, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997;176:892-8.
49. Kesson AM, Ferguson JK, Rawlinson WD, et al. Progressive vaccinia treated with ribavirin and vaccinia immune globulin. Clin Infect Dis 1997;25:911-4.
50. Smee DF, Sidwell RW, Kefauver D, et al. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother 2002;46:21329-35.
51. Jabs DA, Enger C, Forman M, et al, for The Cytomegalovirus Retinitis and Viral Resistance Study Group. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. Antimicrob Agents Chemother 1998;42:2240-4.
52. Smee DF, Barnett BB, Sidwell RW, et al. Antiviral activities of nucleosides and nucleotides against wildtype and drug-resistant strains of murine cytomegalovirus. Antivir Res 1995;26:1-9.
53. Tatti KM, Stang H, Bamard D, et al. Mutations occur in highly conserved domains of murine cytomegalovirus DNA polymerase in cidofovir- and lobucavirresistant strains. Antivir Res 1998;37:A70.
54. Sullivan V, Biron KK, Talarico C, et al. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Chemother 1993;37:19-25.
55. Cohen J. Blocking small pox. A second defense. Science 2001;294:500.
56. De Clercq E, Holy A, Rosenberg I. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrob Agents Chemother 1989;33:185-91.
57. Neyts J, De Clercq E. Efficacy of (S)-I-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J Med Virol 1993;41:242-6.
58. Heymann DL, Szczeniowski M, Esteves K. Re-emergence of monkeypox in Africa: a review of the past six years. Br Med Bull 1998;54:693-702.
59. Bradbury J. Orally available cidofovir derivative active against smallpox. Lancet 2002;359:1041.